+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Benralizumab"

Nasal Polyps Treatment Market Report 2025 - Product Thumbnail Image

Nasal Polyps Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
FASENRA Market Size, Emerging Insight, and Forecast to 2032 - Product Thumbnail Image

FASENRA Market Size, Emerging Insight, and Forecast to 2032

  • Report
  • December 2024
  • 30 Pages
  • Global
From
From
From
From
Severe Asthma: Eight-Market Drug Forecast and Market Analysis - Product Thumbnail Image

Severe Asthma: Eight-Market Drug Forecast and Market Analysis

  • Report
  • February 2025
  • 135 Pages
  • Global
From
Benralizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Benralizumab Emerging Drug Insight and Market Forecast - 2032

  • Report
  • September 2022
  • 30 Pages
  • Global
From
From
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 220 Pages
  • Global
From
Bronchiectasis - Pipeline Insight, 2024 - Product Thumbnail Image

Bronchiectasis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 70 Pages
  • Global
From
Nasal Polyposis - Pipeline Insight, 2024 - Product Thumbnail Image

Nasal Polyposis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
From
Drug Overview: Fasenra - Product Thumbnail Image

Drug Overview: Fasenra

  • Report
  • February 2018
  • 23 Pages
  • Global
From
  • 19 Results (Page 1 of 1)
Loading Indicator

Benralizumab is a monoclonal antibody used to treat severe asthma. It is a type of biologic drug, which works by targeting and blocking a specific protein in the body that is involved in the inflammation process. Benralizumab is administered as an intravenous infusion and is used in combination with other asthma medications. It is approved for use in adults and adolescents aged 12 years and older. Benralizumab is used to treat severe asthma that is not adequately controlled with inhaled corticosteroids and long-acting beta-agonists. It is also used to reduce the frequency of exacerbations in patients with severe asthma. Benralizumab is a relatively new drug and is still being studied to determine its long-term safety and efficacy. In the Benralizumab market, some of the major players include AstraZeneca, GlaxoSmithKline, Sanofi, and Teva Pharmaceuticals. Other companies involved in the market include Boehringer Ingelheim, Merck, and Novartis. Show Less Read more